Breast cancer: HER-2/neupeptide vaccine shows strong response in patients, regardless of HER-2 levels

Abstract

▪ A Phase II trial reported at the conference demonstrated a strong immune response to the HER-2/neupeptide vaccine E75 in breast cancer patients, both when the tumour was expressing high and low levels of HER-2/neuprotein.